Publications by authors named "Mark Barok"

Claim this Profile
D
Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.
Narjes Yazdi, Negar Pourjamal, Riku Katainen, Juho Väänänen, Jun Dai, Mark Barok

Cancer Lett· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the letter to the editor titled: "Polyploid giant cancer cells: unveiling a latent axis of resistance and tumor evolution in HER2-targeted therapy".
Mark Barok, Narjes Yazdi, Heikki Joensuu

Cancer Lett· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering.
Olga Bednova, Jessica Pougoue Ketchemen, Hazem Mslati, Mark Barok, Heikki Joensuu

Biomolecules· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan.
Negar Pourjamal, Vadim Le Joncour, György Vereb, Cilla Honkamaki, Jorma Isola, Mark Barok

Transl Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Negar Pourjamal, Narjes Yazdi, Aleksi Halme, Vadim Le Joncour, Pirjo Laakkonen, Mark Barok

Clin Exp Metastasis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer.
Sherif Samer Attalla, Jonathan Boucher, Hailey Proud, Tarek Taifour, Dongmei Zuo, Mark Barok

Cancer Immunol Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
Mark Barok, Maija Puhka, Narjes Yazdi, Heikki Joensuu

J Extracell Vesicles· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Mark Barok, Vadim Le Joncour, Ana Martins, Jorma Isola, Marko Salmikangas

Cancer Lett· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
Vadim Le Joncour, Ana Martins, Maija Puhka, Jorma Isola, Marko Salmikangas, Mark Barok

Mol Cancer Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.
Mark Barok, Maija Puhka, Gyorgy Vereb, Janos Szollosi, Jorma Isola

BMC Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.
Satu Luhtala, Synnöve Staff, Mark Barok, Minna Tanner, Jorma Isola

Appl Immunohistochem Mol Morphol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab emtansine: mechanisms of action and drug resistance.
Mark Barok, Heikki Joensuu, Jorma Isola

Breast Cancer Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Mark Barok, Minna Tanner, Katri Köninki, Jorma Isola

Cancer Lett· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Mark Barok, Minna Tanner, Katri Köninki, Jorma Isola

Breast Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steps in metastasis research: analyzing, collecting, and culturing circulating tumor cells.
Márk Barok, János Szollosi

Cytometry A· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Katri Köninki, Mark Barok, Minna Tanner, Synnöve Staff, Jukka Pitkänen

Cancer Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a novel, trastuzumab resistant human breast cancer cell line.
Mark Barok, Margit Balazs, Viktoria Lazar, Zsuzsa Rakosy, Eniko Toth

Front Biosci (Elite Ed)· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Die hard: are cancer stem cells the Bruce Willises of tumor biology?
Akos Fábián, Márk Barok, György Vereb, János Szöllosi

Cytometry A· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.
Zsuzsanna Pályi-Krekk, Márk Barok, Tamás Kovács, Hideyuki Saya, Osamu Nagano

Cancer Lett· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ErbB-directed immunotherapy: antibodies in current practice and promising new agents.
Elza Friedländer, Márk Barok, János Szöllosi, György Vereb

Immunol Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
Márk Barok, Margit Balázs, Péter Nagy, Zsuzsa Rákosy, Andrea Treszl

Cancer Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
Zsuzsanna Pályi-Krekk, Márk Barok, Jorma Isola, Markku Tammi, János Szöllosi

Eur J Cancer· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis.
Zsuzsa Rákosy, Laura Vízkeleti, Szilvia Ecsedi, Zoltán Vokó, Agnes Bégány, Márk Barok

Int J Cancer· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Márk Barok, Jorma Isola, Zsuzsanna Pályi-Krekk, Péter Nagy, István Juhász

Mol Cancer Ther· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis